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Abstract
We investigated the biological role of thymidine
phosphorylase (TP), an angiogenic factor, in gastric
cancer cell migration and invasion and explored a
therapeutic approach for high TP-expressing tumors
using TP enzymatic inhibitor (TPI) and rapamycin. We
established TP cDNA overexpressing gastric cancer
cell lines (MKN-45/TP and YCC-3/TP) and did invasion
and adhesion assays with Matrigel-coated transwell
membranes. The related signal pathway using
recombinant human TP (rhTP), deoxy-D-ribose (D-dRib),
and signal pathway inhibitors (wortmannin, LY294002,
and rapamycin) was investigated. First, AGS and MKN-1
gastric cancer cell lines showed dose-dependent
up-regulation of invasiveness through Matrigel following
treatment with rhTP or D-dRib. TP-overexpressing
cancer cell lines displayed increased migration and
invasion activity, which doubled with rhTP and D-dRib
treatment. This activity depended on the enzymatic
activity of TP, and TP stimulated the adhesion of
cancer cells onto Matrigel and induced actin filament
remodeling. Finally, we showed that this activity is
related to increased phosphatidylinositol 3-kinase
activity in TP-overexpressing cells and that combination
treatment with rapamycin and TP enzymatic inhibitor
produces an additive effect to abrogate TP-induced
invasion. Taken together, TP increases the migration
and invasion of gastric cancer cells, especially in
TP-expressing cells. Therapies targeting TP might
diminish the propensity for invasion and metastasis
in gastric cancer. (Mol Cancer Res 2008;6(10):1554–66)
Introduction
Migration and invasion of cancer cells, important charac-
teristics associated with malignancy, are involved in the genesis
of metastatic disease. Cell migration and invasion depend on
cellular interactions with the extracellular matrix and are further
regulated by factors produced and secreted by tumor cells and
the surrounding stromal cells. Thymidine phosphorylase (TP) is
a nucleoside metabolism enzyme, identical to the angiogenic
factor platelet-derived endothelial cell growth factor (1). TP
catalyzes the breakdown of thymidine to thymine and the
sugar 2-deoxy-D-ribose-1-phosphate and induces endothelial
cell chemotaxis in vitro and angiogenesis in vivo (1). TP
modulates both angiogenesis and apoptosis under hypoxic
conditions, suggesting that TP plays an important role in
cancer progression (2, 3). The activity and expression of TP in
carcinoma of the esophagus, stomach, colorectum, pancreas,
and lung are significantly higher than in the adjacent nonneo-
plastic tissue (4).
TP is expressed not only in tumor cells but also in tumor-
associated stromal cells. Several investigations have suggested
that such stromal expression is substantially associated with
an unfavorable prognosis in various cancers (5). However, a
correlation between the expression and activity of TP and
cancer progression, especially invasion and metastasis, has been
observed mostly from analyses using clinical samples. High TP
expression in the primary tumor is a risk factor for both hepatic
and lymph node metastasis in patients with gastric adeno-
carcinoma (6, 7). Significant correlations have been observed
between TP expression and extrapancreatic neural plexus
invasion or the presence of postoperative hepatic metastasis
in patients with ductal adenocarcinoma of the pancreas (8). TP
mRNA levels are 33-fold higher in invasive bladder cancer than
in superficial tumors and 260-fold higher than in normal
bladder tissue (9). A few preclinical studies have shown that
transfection of TP cDNA into the RT112 bladder cancer cell
line transforms its superficial phenotype into an invasive one
(10). Moreover, the TP-overexpressing KB head and neck
cancer cell line displays a greater metastatic tendency to the
liver in an animal model (11). All these findings imply that TP
contributes to the invasion and metastasis of cancer cells
through mechanisms other than angiogenesis, although signi-
ficantly less is known about the biological action of TP in
this respect. Furthermore, recent studies have shown that
TP enzymatic inhibitor (TPI) can suppress chemotaxis and
basement membrane invasion of cancer cells (12). Previously,
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we have shown that 2-deoxy-D-ribose (D-dRib), which is a
dephosphorylation product of 2-deoxy-D-ribose-1-phosphate, is
a downstream mediator of TP functions (2, 13).
Gastric adenocarcinoma is the second most common cause
of cancer-related mortality worldwide (14). Even with the rapid
advancement of treatment options, the prognosis for gastric
cancer is still unsatisfactory due to early metastasis and
recurrence and the highly invasive and metastatic nature of
gastric cancers. The molecular basis behind the induction of
invasive activity remains largely unknown. In this study, we
investigated the biological role of TP in cancer cell invasion in
gastric adenocarcinoma, and we explored a therapeutic
approach for high TP-expressing tumors using TPI and
rapamycin as antimetastatic therapy.
Results
Relationship between TP Expression and Gastric Cancer
Cell Invasion Activity through Matrigel
First, we investigated the protein expression of TP in gastric
cancer cell lines. TP expression was detected in 6 (YCC-2,
YCC-6, YCC-9, YCC-16, AGS, and NCI-N87) of 12 cell lines.
When the cell lines were divided into two groups according to
TP expression, 321 F 213 cells per well migrated through
Matrigel after 24 hours in the TP-expressing group compared
with 132 F 73 cells per well in the TP-nonexpressing group
(P = 0.067).
Next, we examined the influence of TP on the invasiveness
of gastric cancer cells using a Matrigel-coated transwell assay.
When the lower chamber was treated with recombinant human
TP (rhTP) or D-dRib, the catalytic product of thymidine by TP,
TP-expressing AGS cells showed dose-dependent up-regulation
of invasion activity through Matrigel. This activity peaked at
2.6- and 2.4-fold above the basal level with 40 ng/mL rhTP or
40 Amol/L D-dRib, respectively (Fig. 1A). MKN-1 cells, which
had no detectable expression of TP, also showed dose-
dependent up-regulation of invasiveness, although the effect
was not remarkable as with AGS cells. Invasive activity
increased 1.6- and 1.7-fold above the basal level after treat-
ment with 40 ng/mL rhTP or 40 Amol/L D-dRib, respectively
(Fig. 1B). These findings suggest that both TP and D-dRib
influence the invasion activity of cancer cells and that this
activity might be intrinsic for TP.
TP Expression in Cancer Cells Promotes Invasion Activity
through Matrigel
To further analyze the biological roles of cancer cell–
intrinsic TP in migration and invasion, we established two
TP-overexpressing gastric cancer cell lines (YCC-3/TP and
MKN-45/TP) that expressed TP more highly than their
respective mock-transfected counterparts (YCC-3/CV and
MKN-45/CV; Fig. 2A). The concentration of TP was 5.8- and
4.3-fold higher in MKN-45/TP and YCC-3/TP cells, respec-
tively, compared with each mock transfectant (data not shown).
Next, we investigated whether the additional TP expression
affected cell growth. The two TP-overexpressing transfectants
had significantly more rapid cell growth than their parental or
mock transfectant counterparts. The doubling times of YCC-3/
TP and MKN-45/TP cells were 32 and 33 hours, respectively,
whereas those of YCC-3/CVandMKN-45/CV cells were 37 and
38 hours, respectively (P = 0.012; Fig. 2B).
Migration ability was evaluated using wound-healing assays.
Both TP-overexpressing cell lines displayed increased moti-
lity. A remarkable rate of wound closure was observed in TP-
overexpressing cells compared with control cells (Fig. 3A). In
addition, MKN-45/TP cells showed significant invasion
through Matrigel (1.9-fold) compared with that of MKN-45/
CV or parent cells (P < 0.001; Fig. 3B). This effect was even
greater after treatment with rhTP or D-dRib. Although treatment
in the lower chamber with 40 ng/mL rhTP or 40 Amol/L D-dRib
induced migration in all of the MKN-45–based cell lines (parent
MKN-45, MKN-45/CV, and MKN-45/TP cells), the higher rate
was most pronounced in the MKN-45/TP cells, where it was
2.2- and 3.6-fold compared with untreated MKN-45/TP and
parent cells, respectively (Fig. 3B). These findings suggest that
TP and its catalytic product, D-dRib, can promote cancer cell
invasion depending on the intracellular level of TP.
We next examined whether the enzymatic activity of TP is
required for its invasion-promoting function. We inhibited TP
enzymatic activity with TPI (K i = 2  108 mol/L) and
determined whether it could reverse invasion activity. TPI was
not cytotoxic as previously reported (1, 3). We did not observe
any adverse effects on cell viability with the tetrazole assay up
to 125 Amol/L (data not shown). Pretreatment with 10, 50, and
100 Amol/L of TPI resulted in a dose-dependent abrogation of
TP-induced invasiveness in MKN-45/TP cells, whereas the
parent cells and MKN-45/CV cells were only mildly affected
by TPI (Fig. 4A and B).
TP Promotes Actin Remodeling and Cell Adhesion on
Matrigel
Cancer cell invasion is accompanied by cellular changes in
adhesion to the extracellular matrix and is powered by actin fila-
ment polymerization, remodeling, and subsequent signal trans-
duction. We investigated the effect of TP on cellular adhesion to
the extracellular matrix. When AGS cells were treated with
40 ng/mL rhTP or 40 Amol/L D-dRib, they responded with a
2.3-fold increase in adhesion activity (Fig. 5A). This effect also
depended on the expression level of TP. MKN-45/TP cells
showed greater baseline adhesion activity onto Matrigel than the
mock transfectant or parent cell lines. The effect of TP was more
pronounced, up to 4-fold greater after rhTP or D-dRib treatment
than in untreated parent cells (Fig. 5B).
Next, we examined actin filament remodeling after treatment
with rhTP or D-dRib using immunofluorescence in AGS cells.
As shown in Fig. 5C, untreated AGS cells were round and
lacked a definitive filamentous actin (F-actin) structure. In
contrast, cells treated with either rhTP or D-dRib contained
actin filaments redistributed into rosette- and podia-like
structures. These findings indicate that TP influences the
adhesion activity of cancer cells to the surrounding matrix
while at the same time inducing actin filament remodeling.
TP-Related Invasion Activity Is Dependent on the
Phosphatidylinositol 3-Kinase Pathway
The activation of integrins and their respective signaling
pathways is one of the primary mechanisms for inducing
TP Promotes Gastric Cancer Cell Invasion
Mol Cancer Res 2008;6(10). October 2008
1555
Research. 
on October 29, 2014. © 2008 American Association for Cancermcr.aacrjournals.org Downloaded from 
migration and invasion. We examined whether TP or D-dRib
could enhance focal adhesion formation in cancer cells. We
determined the activity of focal adhesion kinase (FAK) by
assessing the phosphorylation status of Tyr397/576 residues using
immunoblotting. We noted, however, an already high baseline
expression of phosphorylated FAK in untreated condition. The
FAK level was not remarkably different according to time or
dose when the cells were treated with rhTP or D-dRib (data not
shown). Accordingly, we concluded that TP-induced migration
activity is not dependent on FAK.
FIGURE 1. Treatment of
rhTP and D-dRib stimulates
gastric cancer cell migration
through Matrigel. A. Cells
(1  105) of AGS cell line.
B. The same number of
MKN-1 was added to the up-
per compartment of Matrigel-
precoated transwell chamber
and allowed to migrate for 36 h
at 37jC. Cell migration was
stimulated by the addition of
each purified factors of rhTP or
D-dRib to the lower chamber.
Columns, mean; bars, SD. *,
P < 0.01, compared with un-
treated control.
Yu et al.
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Next, we determined if the invasion activity promoted by TP
is mediated by the phosphatidylinositol 3-kinase (PI3K)
pathway. Recent reports have shown that PI3K induces actin
filament remodeling through Akt and p70S6K (15, 16). When
AGS cells were treated with 40 ng/mL rhTP or 40 Amol/L
D-dRib, the level of phosphorylated Akt increased as early as
6 hours after treatment. The levels of phosphorylated p70S6K
also increased (Fig. 6A). TP induced the maximum activity of
p70S6K at 12 hours after treatment, whereas D-dRib induced
earlier p70S6K activity, starting at 6 hours.
We then analyzed the role of the PI3K pathway in TP-
induced invasion activity by determining the effect of PI3K
inhibition on cell migration. AGS cells were pretreated with the
PI3K inhibitors LY294002 and wortmannin for 1 hour before
treatment with rhTP or D-dRib. As expected, the addition of
PI3K inhibitors abrogated the phosphorylation of p70S6K
completely and significantly attenuated the stimulation of
migration by both rhTP and D-dRib (Fig. 6B and C). Treatment
with PI3K inhibitors also reduced the invasion function in
TP-overexpressing cells, such as MKN-45/TP, but not in the
F IGURE 2 . TP - o v e r -
expressing cells displayed
enhanced migration ability. A.
The two TP-overexpressing
gastric cancer cell lines YCC-
3/TP and MKN-45/TP had high
TP expression, as evidenced
by immunoblotting for TP. B.
Doubling times of YCC-3/TP
and MKN-45/TP cells.
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accompanying parental or mock transfectant cell lines (Fig. 6D).
These results indicate that PI3K activation might be required for
TP-related invasion.
TP Invasion Activity Is Inhibited by a Combination of
Mammalian Target of Rapamycin Inhibitor and TPI
We hypothesized that mammalian target of rapamycin
(mTOR), an upstream regulator of p70S6K, would be directly
associated with the TP-related migratory effect. MKN-45/TP
cells showed more mTOR activity than MKN-45/CV cells.
Moreover, pretreatment of cells with 100 nmol/L rapamycin
24 hours before treatment with rhTP or D-dRib significantly
attenuated the mTOR activation induced by rhTP and the
migration effect of both TP and D-dRib (Fig. 7A-C).
Finally, we speculated that attenuation of TP-related
invasion activity could be potentiated if both the innate
enzymatic TP activity of cancer cells and the downstream
signaling pathway for cellular movement were inhibited.
Accordingly, we investigated the additive activity of TPI and
rapamycin in TP-overexpressing cells. As expected, the
simultaneous addition of 100 Amol/L TPI and 100 nmol/L
rapamycin did not induce significant cytotoxicity with the
tetrazole assay (data not shown). As shown in Fig. 7D,
concomitant treatment of TPI and mTOR additively inhibited
invasion activity, which was greater in MKN-45/TP cells
compared with the mock transfectant cell line.
Discussion
This study sought to examine the interaction between TP
expression and invasion activity in cancer cells and to
determine whether the p70S6K pathway plays a role in
FIGURE 3. A. Confluent
monolayers of cells were
scratched with a sterile 200-AL
pipette tip to form a wound
area and then cultured in 0.5%
serum medium for 10 and
24 h. Cell migration distances
were calculated and compared
with the initial distance from
the wound area. B. MKN-45
cells (1  105) were added to
the upper compartment of a
Matrigel-precoated transwell
chamber and al lowed to
migrate for 36 h at 37jC. Cell
migration was stimulated by
the addition of either purified
40 ng/mL rhTP or 40 Amol/L
D-dRib to the lower chamber.
Columns, mean; bars, SD.
*, P < 0.01, compared with
MKN-45 cells; **, P < 0.01,
compared with untreated
controls.
Yu et al.
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regulating TP-induced invasion. TP is a known angiogenic
factor, and despite evidence that it is overexpressed in various
solid tumors, the mechanism by which it promotes angio-
genesis has not been elucidated. TP lacks a signal sequence for
secretion, and there have been no reports that TP exerts
angiogenesis through specific receptors, as most angiogenic
factors do (17). TP releases the monosaccharide 2-deoxy-D-
ribose-1-phosphate, which, after dephosphorylation, can depart
from the cell as the cell-permeable D-dRib. D-dRib also
displays angiogenic activity. Addition of thymidine to platelets
that have high levels of TP gives rise to thymine and D-dRib in
the extracellular medium (18, 19). Consequently, D-dRib
is considered an effector of TP-related angiogenesis in endo-
thelial cells.
To better understand the biological roles of cancer cell–
derived TP and its interaction with stromal TP, we first
investigated TP expression in several gastric cancer cell lines.
We found that TP-expressing cells showed increased invasion
through Matrigel. Notably, YCC-16 cells with high TP
expression showed exceptionally higher levels of invasion.
YCC-16 was first isolated from the blood-circulating cancer
cells of a multiple metastatic cancer patient, implying that this
FIGURE 4. TP-induced
migration ability was depen-
dent on TP enzymatic activity.
MKN-45 cells (1  105) were
added to the upper compart-
ment of a Matrigel-precoated
transwell chamber. TPI was
added at concentrations of
10, 50, and 100 Amol/L to the
upper compartment and cells
were allowed to migrate for
36 h at 37jC. A. Representa-
tive figures of Matrigel. B.
Quantitative results are repre-
sented. Columns, mean; bars,
SD. *, P < 0.01, compared with
TPI-untreated MKN-45/TP
cells.
TP Promotes Gastric Cancer Cell Invasion
Mol Cancer Res 2008;6(10). October 2008
1559
Research. 
on October 29, 2014. © 2008 American Association for Cancermcr.aacrjournals.org Downloaded from 
FIGURE 5. TP-induced migration ability was accompanied by increased adhesion activity related to TP. Cells (1  105) were seeded into a Matrigel-
precoated 96-well plate, and the plate was incubated for 2 h at 36jC. Cell adhesion was stimulated with the addition of 40 ng/mL rhTP or 40 Amol/L D-dRib to
the medium and attached cells were counted. A. AGS cells treated with rhTP and D-dRib. *, P < 0.01, compared with untreated controls. B. MKN-45 cells
treated with rhTP and D-dRib. *, P < 0.01, compared with MKN-45; **, P < 0.01, compared with each cell line untreated. Columns, mean; bars, SD. C. AGS
cells were treated with 40 ng/mL rhTP or 40 Amol/L D-dRib and incubated overnight with primary antibody against F-actin conjugated with Alexa Fluor 488
phalloidin at 4jC. Immunofluorescent images were detected with a confocal fluorescent microscope.
Yu et al.
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cell line reflects the active metastatic process. This finding
provides indirect evidence that TP expression could be related
to cancer cell movement and metastasis.
Cancer patients have elevated plasma TP levels (20).
Although TP is not a secreted protein, high cellular turnover
and substantial cell necrosis are thought to occur inside solid
tumors, permitting intracellular enzymes to spill into the
plasma, thereby raising plasma TP. For these reasons, we
assumed that intracellular TP activity was proportional to the
amount of D-dRib produced, although we did not directly
measure the amount of D-dRib produced in TP-overexpressing
cells (21). We observed that the addition of TP or D-dRib
promoted invasion of gastric cancer cells and that this activity
was more pronounced in TP-overexpressing cells. Our
experimental treatment with TP or D-dRib in culture medium
was designed to mimic a TP-rich microenvironment. In
tumors, extracellular TP and metabolites of thymidine,
including D-dRib and oxygen radicals, seem to either interact
with cancer cells by various adhesion and chemotactic
molecules or activate some signal pathway for invasion.
Accordingly, we speculated that TP-expressing cells could
potentiate an extracellular, TP-rich microenvironment. At
present, we have very limited information about the roles of
intracellular and extracellular TP, which may be different.
Moreover, the proximal action site of TP/D-dRib within the
cell remains unknown. Intracellular TP is a marker of high
cellular turnover that may regulate another, as yet unidentified,
signal pathway to promote cancer progression and metastasis.
TP-dependent production of D-dRib may provide an energy
source for cancer cells and chemotactic information for
invasion. High-throughput techniques for universal gene or
protein expression could help identify the holistic factors
involved.
Based on these findings, we examined whether the
observed invasion activity was related to the enzymatic
activity of TP. We previously showed that TP-overexpressing
cell lines have high enzymatic activity (22). Treatment with
TPI attenuated the migration-promoting effect of TP, espe-
cially in TP-overexpressing MKN-45 cells. AGS cells with
weak TP expression also displayed attenuated migration with
TPI, although not as much as in MKN-45/TP. MKN-45/CV or
parent cells without detectable TP expression did not respond
to TPI, suggesting that TP-related invasion activity is
primarily dependent on innate TP activity. Intercellular
variability of TP expression and its correlation with motility
were also associated with enzymatic activity. Cancer cell
migration is a process involving cell attachment and the
degradation of tissue barriers caused by various proteolytic
enzymes. Recent studies suggest that TP promotes the
secretion of matrix metalloproteinase-1 through oxidative
stress and that there is a correlation between TP and matrix
metalloproteinase-2 mRNA levels (23, 24). TP might promote
the expression of matrix metalloproteinases, leading to cancer
cell invasion and metastatic potential.
We speculated that the alteration of adhesion and actin
remodeling act as functional indicators of migrating cancer
cells. We showed that adhesion ability to Matrigel was also
increased by treatment with TP or D-dRib, implying that the
activation of signal pathways by contact with the extracellular
matrix could play a major role in TP-related ability. These
pathways could be divided into those that are focal adhesion
related or growth factor related. Hotchkiss et al. (25) reported
that TP and D-dRib stimulate the formation of focal adhesions
and activate specific integrins for endothelial cell migration. We
did not observe FAK activation in our experiments. FAK is
activated by a phosphorylated tyrosine, and its own kinase
activity is higher in cancer cells. The cells used in this
experiment had a considerable amount of baseline FAK
activation (26, 27).
Because TP and D-dRib are not present in normal serum,
there is good reason to suspect that D-dRib attracts cells by
acting as an energy source. Pig erythrocytes take up D-dRib
more rapidly than D-ribose, suggesting that pentose sugars
may enter the cell without a transporter because D-dRib is the
less polar molecule (28, 29). Accordingly, we hypothesized
that TP or D-dRib was able to modify the phosphorylation
status of molecules involved in cancer angiogenesis or
progression.
The finding that rapamycin inhibits TP-stimulated migra-
tion implicates the activation of p70S6K in this cellular
response, which is consistent with other works showing that
rapamycin inhibits the migration of vascular smooth muscle
cells or endothelial cells (30-32). In those studies, the effects
of rapamycin were primarily mediated by p27kip, a cell cycle
regulator that may be a downstream target of mTOR. We
found that TP-overexpressing cells had significantly more
rapid cell growth than parental or mock transfectant cells. The
relationship between TP expression and cell proliferation
remains debatable. Early reports asserted that TP enhances
tumor growth in vivo but has no effect on growth in vitro (33,
34). More recent reports, however, suggest that high TP
expression may modulate the cell cycle in head and neck
cancer cells in association with the down-regulation of p27kip
(35). The mechanism behind the rapid cell growth in our TP-
expressing cells was outside the scope of our study, although
this is the first report that TP may regulate cell proliferation in
gastric cancer.
It seems unlikely that the effects of mTOR on migration in
such cells are mediated exclusively by p27kip, and we cannot
exclude the possibility that a target of mTOR other than p70S6K
mediates the effects of rapamycin on cancer cell motility. We
also observed that treatment with rapamycin attenuated, but
did not completely abrogate, TP-stimulated migration activity.
We have been unable to identify the mechanism by which
rapamycin influences TP-induced migration ability, but recent
studies suggest that the phospholipase D pathway may play a
critical role. Phospholipase D activates p70S6K, an observation
that may be explained by the phosphatidic acid–mediated
activation of mTOR (36, 37). Some evidence suggests that
phospholipase D activates the PI3K signaling pathway (38).
Our experiments revealed Akt activation by rhTP and D-dRib,
and TP-overexpressing cells displayed increased Akt activity,
consistent with the findings of previous reports (39). It is
possible, therefore, that rapamycin treatment may be required
for the phospholipase D pathway in actin cytoskeletal
reorganization.
The ability of both TPI and rapamycin to abrogate TP-
induced migration has implications for clinical application. A
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combined TPI and trifluorothymidine (TAS-102) agent is
currently undergoing phase I studies (40). Our study provides
the rationale for antimetastatic therapy combining a mTOR
inhibitor (signal blocker) with TPI (enzymatic inhibitor) to
increase potency, especially in high TP-expressing tumors. To
conclude, this study showed that TP and D-dRib increased the
invasion activity of gastric cancer cells, especially in TP-over-
expressing cells. TP could be a therapeutic target for
diminishing the propensity for invasion and metastasis in
gastric cancer.
Materials and Methods
Reagents and Antibodies
rhTP was purchased from R&D Systems. D-dRib came
from Sigma. Matrigel was purchased from BD Biosciences.
TPI, a previously described specific inhibitor of TP activity,
was synthesized by Taiho Pharmaceutical Co. Ltd. (11).
The PI3K inhibitors wortmannin and LY294002 were supplied
by Sigma and Calbiochem, respectively. Rapamycin was
supplied by Sigma. Monoclonal antibody for immunoblotting
and ELISA against TP was purchased from R&D Systems.
Antibodies against Akt, phosphorylated Akt (Thr473, Thr308),
p70 S6K, phosphorylated p70S6K, and mTOR were purchased
from Cell Signaling. Anti-phosphorylated mTOR antibody
came from Biosource.
Cell Culture
The human gastric cancer cell lines AGS and NCI-N87
were supplied by the American Type Culture Collection. The
gastric cancer cell lines MKN-1 and MKN-45 were provided
by the Korean Cell Line Bank. YCC-1, YCC-2, YCC-3,
YCC-6, YCC-7, YCC-9, YCC-11, and YCC-16 were gastric
cancer cell lines established by Yonsei Cancer Center (Seoul,
Korea) from advanced gastric cancer patients through
isolation from ascites (YCC-1, YCC-2, YCC-3, YCC-6,
YCC-7, YCC-9, and YCC-11) or peripheral blood (YCC-16).
All cell lines were maintained in RPMI 1640 (Nissui)
supplemented with 10% fetal bovine serum, 100 units/mL
ampicillin, 100 Ag/mL streptomycin, and 2 mmol/L gluta-
mine (Life Technologies) in a 5% CO2 humidified atmo-
sphere at 37jC.
Establishment of TP-Overexpressing Cell Lines
Full-length TP cDNA expression vector (RSV/TP) and the
empty vector [RSV; previously described (39)] were provided
by Prof. Akiyama (Kagoshima University, Kagoshima, Japan).
The plasmid was transfected into MKN-45 and YCC-3 cells by
electroporation. After selection with geneticin, the expression
of TP in each clone was determined by immunoblotting. A TP-
positive clone (MKN-45/TP or YCC-3/TP) and a control
vector– transfected clone (MKN-45/CV or YCC-3/CV) were
selected for further analysis.
ELISA for TP
TP protein expression was analyzed by a direct (sandwich)
ELISA with modifications, according to the manufacturer’s
instructions. Samples and the standard were diluted to the
desired concentration with coating buffer and dispensed into
each microplate well. After overnight incubation at 4jC, the
plates were blocked for 1.5 h at 37jC. Anti-human TP primary
antibody was added to each well, and the plates were incubated
for 2 h at room temperature. After the plates were washed three
times, goat anti-mouse IgG serum conjugated with peroxidase
was added, and the plates were incubated for an additional hour
at room temperature. A substrate reaction was done with a
solution of the 3,3¶,5,5¶-tetramethylbenzidine substrate system
(R&D Systems). The peroxide reaction was terminated with
1 mol/L phosphoric acid solution, absorbance was measured at
450 nm, and the TP level was determined with reference to the
standard curve.
Cell Proliferation Assay
To measure cell growth, 1  104 cells were seeded on 24-
well plates and cultured for 24 h. The cells were then cultured
for 5 d in 10% fetal bovine serum. The cell growth rate was
evaluated by trypan blue assay (Life Technologies) in
triplicate. Doubling time was calculated by the following
equation: TD = T  log2/log(N/N0), where TD = doubling
time, T = time interval, N = end point cell number, and
N0 = initial cell number.
Wound-Healing Assay
Wound-healing assays were done according to the
suggested methods. After cells were cultured to a 100%
confluent monolayer in six-well tissue culture plates for 24 h,
a sterile 200-AL pipette tip was used to scratch the cell
monolayer to form a wound area. The wells were then cul-
tured in medium with 0.5% serum for 8 and 24 h and then
fixed with formalin. Migration and cell movement throughout
the wound area was examined. The migration distances were
calculated and compared with the initial size of the wound
area, and the results are presented as a percentage of the
closed wound.
Invasion Assay Using Transwell Filters
We conducted a modified version of the standard transfilter
assay for invasion. Transwell filters (diameter, 6.5 mm; pore
size, 8 Am; BD Biosciences) were coated on the lower side with
8 Ag/AL Matrigel and placed on a 24-well plate containing
medium supplemented with 0.1% bovine serum albumin.
FIGURE 6. TP induces cancer cell migration via the PI3K pathway. A. AGS cells were treated with either 40 ng/mL rhTP or 40 Amol/L D-dRib, and the
level of phosphorylated Akt (Y473) and p70S6K was detected by immunoblotting. B. AGS cells were pretreated with the PI3K inhibitors LY294002 and
wortmannin for 1 h before treatment with rhTP or D-dRib. Cell lysates were obtained at 6 and 12 h after PI3K inhibitor treatment, and changes in the
phosphorylation of p70S6K were detected by immunoblotting. C. AGS cells were preincubated with LY294002 (20 and 40 Amol/L) or wortmannin (500 nmol/L
and 1 Amol/L) and treated with either 40 ng/mL rhTP or 40 Amol/L D-dRib in the lower chamber. Cells were allowed to migrate for 36 h at 37jC. *, P < 0.01,
compared with untreated control. D. MKN-45 cells were preincubated with LY294002 (40 Amol/L) or wortmannin (500 nmol/L) and treated with either
40 ng/mL rhTP or 40 Amol/L D-dRib in the lower chamber. Cells were allowed to migrate for 36 h at 37jC. Columns, mean; bars, SD. *, P < 0.01, compared
with each cell line untreated.
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Cells were harvested with a cell dissociation solution (Sigma)
and suspended in medium with 1% bovine serum albumin.
Cells (1  105) were added to the upper compartment of a
transwell chamber and allowed to migrate for 36 h at 37jC.
Cell migration was stimulated by the addition of purified
factors (rhTP or D-dRib) to the lower chamber. For protocols
involving drug inhibitor treatment, the inhibitors were added
to the upper compartment. After 36 h, nonmigrated cells on
the upper side of membrane were removed with a cotton swab,
and migrated cells on the bottom surface of the membrane
were fixed in 3.7% paraformaldehyde in PBS and stained with
crystal violet for 10 min at room temperature. Cell migration
was quantified by counting the number of cells in three
inserts. The data are expressed as the average number of cells
per insert.
Cell-Matrigel Adhesion Assay
Harvested cells were suspended in medium with 0.1%
bovine serum albumin, and 1  105 cells were seeded into
8 Ag/AL Matrigel-precoated 96-well plates that were then
incubated for 2 h at 36jC. Cell adhesion was stimulated by
the addition of rhTP or D-dRib to the medium. After 2 h, the
medium was removed and the attached cells were stained with
crystal violet for 10 min at room temperature. Attached cells
were counted.
Immunofluorescent Staining for F-Actin
Cells were seeded on Matrigel and stimulated with rhTP
(40 ng/mL), D-dRib (40 Amol/L), or medium only (negative
control) for 12 h. Cells were fixed with 3.7% paraformaldehyde
in PBS for 10 min and permeabilized by incubation with
FIGURE 7. The migration ability induced by TP was inhibited by combination treatment with a mTOR inhibitor and TPI. A. MKN-45/CV and MKN-45/TP
cells were treated with 40 ng/mL rhTP, and 16 time-dependent levels of phosphorylated mTOR were detected by immunoblotting. B. MKN-45/CV and MKN-
45/TP cells were pretreated with 100 nmol/L of the mTOR inhibitor rapamycin for 1 h before treatment with 40 ng/mL rhTP. Cell lysates were obtained at 6,
12, and 24 h after treatment with the PI3K inhibitors, and changes in the phosphorylation of mTOR and p70S6K were detected by immunoblotting. C.MKN-45
cells were preincubated with 100 nmol/L rapamycin and treated with rhTP or D-dRib in the lower chamber. Cells were allowed to migrate for 36 h at 37jC.
Columns, mean; bars, SD. *, P < 0.01, compared with MKN-45/CV cells; **, P < 0.01, compared with each cell line untreated; ***, P < 0.01, compared with
each cell line treated with rhTP or D-dRib. D. MKN-45 cells were preincubated concurrently with 100 nmol/L rapamycin and 100 Amol/L TPI along with either
40 ng/mL rhTP or 40 Amol/L D-dRib in the lower chamber. Cells were allowed to migrate for 36 h at 37jC. Columns, mean; bars, SD. *, P < 0.01, compared
with untreated controls; **, P < 0.01, compared with each cell line untreated; ***, P < 0.01, compared with each cell line treated with rhTP or D-dRib.
Yu et al.
Mol Cancer Res 2008;6(10). October 2008
1564
Research. 
on October 29, 2014. © 2008 American Association for Cancermcr.aacrjournals.org Downloaded from 
0.1% Triton X-100 in PBS (PBS-B) for 10 min. Cells were
washed thrice with PBS and blocked with 10% fetal bovine
serum in PBS-B for 60 min at room temperature. To stain
F-actin, cells were incubated with primary antibody against
F-actin conjugated with Alexa Fluor 488 phalloidin (Invitro-
gen) overnight at 4jC. Images were detected with a Zeiss
LSM 510 Meta confocal fluorescent microscope.
Immunoblotting
Exponentially growing cells were seeded at 1  106 per 60-
cm2 dish and treated with rhTP (40 ng/mL) or D-dRib
(40 Amol/L) for 36 h. Cells were harvested and resuspended in
lysis buffer [50 mmol/LTris-HCl (pH 7.4), 150 mmol/L NaCl, 1
mmol/L EDTA, 1% NP40, 1 mmol/L sodium ortho-
vanadate, 1 mmol/L NaF, 10 Ag/mL aprotinin, 10 Ag/mL leu-
peptin, 1 mmol/L phenylmethylsulfonyl fluoride]. Whole-cell
lysates were subjected to SDS-PAGE and blotted onto poly-
vinylidene difluoride membranes. Each membrane was then
incubated with appropriate primary antibody overnight at 4jC
followed by a peroxidase-linked secondary antibody for 1 h at
room temperature. Membranes were developed by chemilumi-
nescence according to the manufacturer’s protocol (Amersham).
Statistical Analysis
Quantitative data are represented as the mean F SD of at
least three independent experiments. Statistical comparisons
were done using Student’s t test. Differences were regarded as
significant when the P value was <0.05.
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